Use of cannabidiol in anxiety and anxiety-related disorders

Published:November 19, 2019DOI:



      Cannabidiol (CBD) has a proposed novel role in the management of anxiety owing to its actions on the endocannabinoid system. The purpose of this systematic review was to evaluate the current evidence on the safety and efficacy of CBD in anxiety and anxiety-related disorders.

      Data sources

      A literature search was conducted on PubMed, Google Scholar, and International Pharmaceutical Abstracts from database inception through June 2019. A bibliographic search of relevant articles was also conducted.

      Study selection

      Articles published from case reports, case series, or randomized controlled trials on human subjects were included in the review if they examined the safety and efficacy of CBD therapy in anxiety and anxiety-related disorders.

      Data extraction

      Two reviewers independently extracted the following data from the articles: year of publication; study design; patient characteristics (sex; type of anxiety disorder; use of concomitant anxiolytic therapy); dosing strategy and route of CBD administration; and safety and efficacy outcomes.


      Eight articles were included in the review: 6 small, randomized controlled trials; 1 case series; and 1 case report. These studies examined the role of CBD in the anxiety response of healthy volunteers; in generalized anxiety disorder; in social anxiety disorder; and in the anxiety component of posttraumatic stress syndrome. No articles that evaluated CBD in panic disorder, specific phobia, separation anxiety, and obsessive-compulsive disorder were identified. In the studies, CBD was administered orally as a capsule or as a sublingual spray and as either monotherapy or adjunctive therapy. Doses varied widely, with studies employing fixed CBD doses ranging from 6 mg to 400 mg per dose. Various anxiety assessment scales were used in the studies to assess efficacy, with CBD demonstrating improved clinical outcomes among the instruments. In general, CBD was well-tolerated and associated with minimal adverse effects, with the most commonly noted adverse effects being fatigue and sedation.


      CBD has a promising role as alternative therapy in the management of anxiety disorders. However, more studies with standardized approaches to dosing and clinical outcome measurements are needed to determine the appropriate dosing strategy for CBD and its place in therapy.
      To read this article in full you will need to make a payment
      APhA Member Login
      APhA Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Tovote P.
        • Fadok J.P.
        • Lüthi A.
        Neuronal circuits for fear and anxiety.
        Nat Rev Neurosci. 2015; 16: 317-331
        • Martin E.I.
        • Ressler K.J.
        • Binder E.
        • Nemeroff C.B.
        The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology.
        Psychiatr Clin North Am. 2009; 32: 549-575
        • Kessler R.C.
        • Berglund P.
        • Demler O.
        • Jin R.
        • Merikangas K.R.
        • Walters E.E.
        Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication.
        Arch Gen Psychiatry. 2005; 62: 593-602
        • Papagianni E.P.
        • Stevenson C.W.
        Cannabinoid regulation of fear and anxiety: an update.
        Curr Psychiatry Rep. 2019; 21: 38
        • Murrough J.W.
        • Yaqubi S.
        • Sayed S.
        • Charney D.S.
        Emerging drugs for the treatment of anxiety.
        Expert Opin Emerg Drugs. 2015; 20: 393-406
        • Griebel G.
        • Holmes A.
        50 years of hurdles and hope in anxiolytic drug discovery.
        Nat Rev Drug Discov. 2013; 12: 667-687
        • LeDoux J.E.
        • Pine D.S.
        Using neuroscience to help understand fear and anxiety: a two-system framework.
        Am J Psychiatry. 2016; 173: 1083-1093
        • Blessing E.M.
        • Steenkamp M.M.
        • Manzanares J.
        • Marmar C.R.
        Cannabidiol as a potential treatment for anxiety disorders.
        Neurotherapeutics. 2015; 12: 825-836
        • de Mello Schier A.R.
        • de Oliveira Ribeiro N.P.
        • Coutinho D.S.
        • et al.
        Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.
        CNS Neurol Disord Drug Targets. 2014; 13: 953-960
        • Campos A.C.
        • Ferreira F.R.
        • Guimarães F.S.
        Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors.
        J Psychiatr Res. 2012; 46: 1501-1510
        • Patel S.
        • Hill M.N.
        • Cheer J.F.
        • Wotjak C.T.
        • Holmes A.
        The endocannabiniod system as a target for novel anxiolytic drugs.
        Neurosci Biobehav Rev. 2017; 76: 56-66
        • Izzo A.A.
        • Borrelli F.
        • Capasso R.
        • Di Marzo V.
        • Mechoulam R.
        Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.
        Trends Pharmacol Sci. 2009; 30: 515-527
        • Iffland K.
        • Grotenhermen F.
        An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies.
        Cannabis Cannabinoid Res. 2017; 2: 139-154
        • Epidiolex
        (Cannabidiol) [Prescribing Information].
        Greenwich Biosciences, Carlsbad, CA2018 (Available at: Accessed December 4 2019)
        • Schiller L.J.
        Scientific data and information about products containing cannabis or cannabis-derived compounds; public hearing; request for comments.
        (Available at:)
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        • PRISMA Group
        Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement.
        PLOS Med. 2009; 6: e1000097
        • Crippa J.A.
        • Zuardi A.W.
        • Garrido G.E.
        • et al.
        Effects of cannabidiol (CBD) on regional cerebral blood flow.
        Neuropsychopharmacology. 2004; 29: 417-426
        • Oathes D.J.
        • Patenaude B.
        • Schatzberg A.F.
        • Etkin A.
        Neurobiological signatures of anxiety and depression in resting-state functional magnetic resonance imaging.
        Biol Psychiatry. 2015; 77: 385-393
        • Shannon S.
        • Lewis N.
        • Lee H.
        • Hughes S.
        Cannabidiol in anxiety and sleep: A large case series.
        Perm J. 2019; 23: 18-041
        • Shannon S.
        • Opila-Lehman J.
        Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: A case report.
        Perm J. 2016; 20: 16-1005
        • Zuardi A.W.
        • Rodrigues N.P.
        • Silva A.L.
        • et al.
        Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life.
        Front Pharmcol. 2017; 8: 259
        • Baldi E.
        • Bucherelli C.
        The inverted "U-shaped" dose-effect relationships in learning and memory: modulation of arousal and consolidation.
        Nonlin Biol Toxicol Med. 2005; 3: 9-21
        • Zuardi A.W.
        • Cosme R.A.
        • Graeff F.G.
        • Guimarães F.S.
        Effects of ipsapirone and cannabidiol on human experimental anxiety.
        J Psychopharmacol. 1993; 7: 82-88
        • Linares I.M.
        • Zuardi A.W.
        • Pereira L.C.
        • et al.
        Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.
        Braz J Psychiatry. 2019; 41: 9-14
        • Bergamaschi M.M.
        • Queiroz R.H.C.
        • Chagas M.H.N.
        • et al.
        Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
        Neuropsychopharmacology. 2011; 36: 1219-1226
        • Crippa J.A.
        • Derenusson G.N.
        • Ferrari T.B.
        • et al.
        Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
        J Psychopharmacol. 2011; 25: 121-130
        • Bhattacharyya S.
        • Morrison P.D.
        • Fusar-Poli P.
        • et al.
        Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.
        Neuropsychopharmacology. 2010; 35: 764-774
        • Fusar-Poli P.
        • Crippa J.A.
        • Bhattacharyya S.
        • et al.
        Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.
        Arch Gen Psychiatry. 2009; 66: 95-105
        • Fusar-Poli P.
        • Allen P.
        • Bhattacharyya S.
        • et al.
        Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.
        Int J Neuropsychopharmacol. 2010; 13: 421-432
        • Karniol I.G.
        • Shirakawa I.
        • Kasinski N.
        • Pfeferman A.
        • Carlini E.A.
        Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man.
        Eur J Pharmacol. 1974; 28: 172-177
        • Martin-Santos R.
        • Crippa J.A.
        • Batalla A.
        • et al.
        Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.
        Curr Pharm Des. 2012; 18: 4966-4979
        • Zuardi A.W.
        • Shirakawa I.
        • Finkelfarb E.
        • Karniol I.G.
        Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.
        Psychopharmacology (Berl). 1982; 76: 245-250
        • Yamaori S.
        • Koeda K.
        • Kushihara M.
        • Hada Y.
        • Yamamoto I.
        • Watanabe K.
        Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.
        Drug Metab Pharmacokinet. 2012; 27: 294-300
        • Rong C.
        • Carmona N.E.
        • Lee Y.L.
        • et al.
        Drug-drug interactions as a result of co-administering Δ9-THC and CBD with other psychotropic agents.
        Expert Opin. Drug Saf. 2018; 17: 51-54
        • Stout S.M.
        • Cimino N.M.
        Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
        Drug Metab Rev. 2014; 46: 86-95
        • Mead A.
        The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
        Epilepsy Behav. 2017; 70: 288-291
        • United States Food and Drug Administration
        2015 warning letters and test results.
        U.S. Food and Drug Administration, Silver Spring, MD2015
        • United States Food and Drug Administration
        2016 warning letters and test results.
        U.S. Food and Drug Administration, Silver Spring, MD2016
        • Vandrey R.
        • Raber J.C.
        • Raber M.E.
        • Douglass B.
        • Miller C.
        • Bonn-Miller M.O.
        Cannabinoid dose and label accuracy in edible medical cannabis products.
        JAMA. 2015; 313: 2491-2493


      Jessica W. Skelley, PharmD, BCACP, Associate Professor of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, Birmingham, AL


      Crystal M. Deas, PharmD, BCPS, Assistant Professor of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, Birmingham, AL


      Zachary Curren, BS, Student Pharmacist, McWhorter School of Pharmacy, Samford University, Birmingham, AL


      Jonathan Ennis, BS, Student Pharmacist, McWhorter School of Pharmacy, Samford University, Birmingham, AL